fentanyl
-
FDA Concerns over TIRF-REMS and Rethinking Access Program
*TIRF-REMS = Transmucosal Immediate Release Fentanyl - Risk Evaluation and Mitigation Strategy ^Patient, Provider, and Pharmacy is required to register with TIRF-REMS Access Program (e.g. Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys) FDA rethinking TIRF-REMS* after nationally renowned...- biDOC
- Thread
- anaesthesiology cancer fda fentanyl pain management pharmacology
- Replies: 10
- Forum: Pain Medicine